Psoriasis and risk of diabetes-associated microvascular and macrovascular complications - 16/05/15
, Annie Guérin, MSc b, Murali Sundaram, MBA, PhD c, Eric Qiong Wu, PhD b, Elizabeth Sara Faust, BA b, Raluca Ionescu-Ittu, PhD b, Parvez Mulani, PhD cAbstract |
Background |
Psoriasis's effect on diabetes onset is well documented, but its effect on course of diabetes is poorly understood.
Objective |
We sought to compare risks of developing microvascular and macrovascular complications between diabetic patients with and without psoriasis.
Methods |
Adults with 2 or more diabetes diagnoses selected from MarketScan databases (Truven Health Analytics Inc, Ann Arbor, MI) (2000-2006) were classified into 2 cohorts: 2 or more psoriasis diagnoses and without psoriasis diagnosis. Patients with psoriasis were matched using propensity score, and exactly matched using age, sex, and diabetes characteristics with patients without psoriasis. Outcomes were compared between cohorts using Cox regression models.
Results |
In all, 6164 diabetic patients with psoriasis (27% moderate to severe) were matched to 6164 diabetic patients without psoriasis. Patients with psoriasis were significantly more likely to develop microvascular events than patients without psoriasis overall (hazard ratio [HR] 1.14, P < .001) and by psoriasis severity (mild: HR 1.13, P = .004; moderate to severe: HR 1.16, P = .038). Risk of macrovascular events was higher for patients without psoriasis overall (HR 1.13, P = .001) and those with mild psoriasis (HR 1.15, P = .003), but not for moderate to severe cases (HR 1.10, P = .210).
Limitations |
Psoriasis to diabetes association may be underestimated.
Conclusion |
Among diabetic patients, psoriasis is generally associated with higher rates of microvascular and macrovascular complications. Greater psoriasis severity did not increase risk of diabetic complications.
Le texte complet de cet article est disponible en PDF.Key words : complications, diabetes, inflammation, macrovascular, microvascular, observational study, psoriasis
Abbreviations used : AE, CEPC, CI, HR, IL, TNF
Plan
| Funding sources: None. |
|
| Disclosure: Dr Armstrong has served as investigator and/or consultant to AbbVie Inc, Amgen, Janssen, Merck, Lilly, and Pfizer. Dr Wu, Ms Faust, Dr Ionescu-Ittu, and Ms Guérin are employed by Analysis Group, which received payment from AbbVie Inc to assist with data analysis. Drs Sundaram and Mulani are employees of AbbVie Inc and may own AbbVie Inc stock or stock options. Design, study conduct, and financial support for the study were provided by AbbVie Inc; AbbVie Inc participated in the interpretation of data, review, and approval of the manuscript; all authors contributed to the development of the publication and maintained control over the final content. |
Vol 72 - N° 6
P. 968 - juin 2015 Retour au numéro
Article précédent
- Evaluating the economic burden of psoriasis in the United States
- Jacqueline Vanderpuye-Orgle, Yang Zhao, Jackie Lu, Anshu Shrestha, Alison Sexton, Seth Seabury, Mark Lebwohl
- Genital psoriasis is associated with significant impairment in quality of life and sexual functioning
- Caitriona Ryan, Muriel Sadlier, Edward De Vol, Mahir Patel, Amanda Abramson Lloyd, Antoinette Day, Aoife Lally, Brian Kirby, Alan Menter
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?